Overview

A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis

Status:
Not yet recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
The study is designed to evaluate the Safety, Tolerability and Pharmacokinetics of ATB1651 in participants with mild to moderate onychomycosis.
Phase:
Phase 1
Details
Lead Sponsor:
AmtixBio Co., Ltd.
Collaborator:
Novotech (Australia) Pty Limited